Among 6 sphingosine-1-phosphate (S1P) receptor modulators evaluated for use in patients with multiple sclerosis (MS), a new meta-analysis shows amiselimod had the highest efficacy. “This network ...

National University of Singapore, Yong Loo Lin School of Medicine Multiple sclerosis (MS) is an autoimmune disease affecting the brain and spinal cord. In MS, the activated immune cells attack myelin, ...

I f you have ulcerative colitis — a type of inflammatory bowel disease (IBD) characterized by stomach pain, fatigue, urgency, and other gut symptoms — you may be familiar with the wide range of ...

Please provide your email address to receive an email when new articles are posted on . The management of multiple sclerosis has improved considerably over the past decade with broadening of the ...

The trafficking of white blood cells called lymphocytes is crucial for controlling our immune response. Maintaining the integrity of high endothelial venules (HEVs) — the gateway for lymphocytes to ...

Priothera has raised €30 million ($35 million) to fund clinical trials of a S1P receptor modulate once in development at Novartis. The drug, mocravimod, will undergo testing in high-risk acute myeloid ...

The FDA approved oral etrasimod (Velsipity) on Friday for treating moderately to severely active ulcerative colitis (UC) in adults, drugmaker Pfizer announced. Approval of the selective ...

Please provide your email address to receive an email when new articles are posted on . Arena Pharmaceuticals announced that etrasimod, its novel, oral selective sphingosine 1-phosphate receptor ...